Deciphera Pharmaceuticals has presented data that confirms the broad spectrum of activity of its pan-KIT and PDGFRα inhibitor, DCC-2618, at the American Association for Cancer Research (AACR) meeting in Washington DC.
Translational data
Dr Filip Janku, PhD, assistant professor, the University of Texas MD Anderson Cancer Center, presented a poster at the meeting that revealed translational results from patients with gastrointestinal stromal tumours (GIST). The results have been collected from the ongoing Phase I, dose escalation study of oral DCC-2618 in advanced solid tumour patients.
“There are limited treatment options available for heavily pre-treated patients with GIST. We are extremely encouraged that in these patients DCC-2618 at doses of 30 mg or 50 mg BID resulted in dramatic reductions or complete clearance from their plasma of cell free (cf) DNA across the spectrum of exons 9, 11, 13, 14, 17 and 18 KIT mutations,” said Michael D, Taylor PhD, Deciphera’s president and CEO. “By inhibiting even difficult to treat secondary drug resistant KIT mutations, such as exon 13 V654A, DCC-2618 offers the potential for more durable responses in patients where mutations confer resistance to other kinase inhibitor therapies.”
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumour drug resistance.